USCOM LIMITED — Board/Management Information 2016

Mar 22, 2016

ASX Media Release

Former J&J Asia Executive Appointed to Uscom Board

Sydney, Australia: 23rd March 2016: Uscom (ASX code: UCM) (the Company or Uscom ), a revenue stage, cardiovascular and pulmonary health technology company, today notified the market of the appointment of Mr Chao Xian (David) He as a Director of Uscom Limited.

Mr He was born in Shanghai and educated in Sydney. For the last 9 years He was based in Shanghai and Singapore as Vice President of Business Development APAC with Johnson & Johnson. Prior to that Mr He was an Associate at McKinsey & Company in Shanghai, then Director of Business Development and External Growth APAC and VP Finance China with AB InBev based in Hong Kong and Shanghai.

Mr He’s achievements include developing market strategy and building the acquisition pipeline for J&J consumer products and leading a number of strategic business acquisitions in the APAC region for the Company. In his time with McKinsey David was involved in a number of M&A and strategy projects, and established his credentials as a deal maker having conceived and executed a number of acquisitions for AB InBev in China.

Mr He’s appointment is strategically conceived to strengthen the connections between Uscom Limited and the Chinese medical market, and utilize Mr He’s experience and local associations to enhance business opportunities for Uscom in China.

Mr He said “Uscom is a recognized brand in China, but currently only reaches a small fraction of the Chinese market. My objective is to focus my experience and connections, acquired from 9 years with J&J China, to increase delivery of Uscom products to all of China. While the USCOM 1A device already has some presence in the market, the release of the Uscom BP+ and Uscom SpiroSonic devices later this year creates real opportunities for Uscom to engage in the lucrative, extensive and rapidly growing Chinese home care and consumer market, and I look forward to being instrumental in growing this opportunity.”

Executive Chairman of Uscom, Associate Professor Rob Phillips said, “This is a commercially progressive appointment for Uscom as China is rapidly assuming the role of the world’s fastest growing medical device market and demands the best of global technologies. Uscom has been in China and I have been involved at an academic, clinical and commercial level for over 10 years. The appointment of David He to the Board confirms our commitment to this rapidly expanding market and the development of our relationships there. With three practice leading suites of clinical medical devices there are great opportunities for David to use his J&J China skills to compliment and enhance our current effective distribution to grow the Uscom China business and strategy. We are delighted to have David join the Uscom Board at such an exciting time in the history of the Company.”

This appointment is part of an Uscom global strategy to appoint high level and experienced leaders in major regional markets and follows the appointment of Mr Stephen Wilson as the Uscom US VP of Business Development last year. Mr Wilson was a former long term VP of Corporate Development for Welch Allyn.

Uscom manufactures and markets the USCOM 1A, the Uscom BP+, and Uscom SpiroSonic digital ultrasonic spirometry technologies. These premium digital devices are changing the way we diagnose and treat cardiovascular and pulmonary diseases, including hypertension, heart failure, asthma, COPD and sleep disorders. The products are integral for optimising management of sepsis and guidance of fluid, inotropes and vasoactive therapies in critical care monitoring, and in clinical and home care delivered asthma and COPD medications.

Uscom Limited (ABN 35 091 028 090) Suite 1, Level 7, 10 Loftus Street , Sydney NSW 2000 Australia , T +612 9247 4144 F +612 9247 8157 www.uscom.com.au

ASX Media Release

About Uscom

Uscom Limited (UCM) is an ASX listed innovative medical technology company specialising in development and marketing of premium cardiovascular and pulmonary medical devices. Uscom has three practice leading suites of devices in the field of cardiac, vascular and pulmonary monitoring; the USCOM 1A, Uscom BP+ and the Uscom SpiroSonic spirometers. All Uscom devices are premium resolution, and deploy innovative and practice leading technologies with FDA, CE, CFDA and TGA regulatory approval, and which are currently being marketed into global distribution networks.

The USCOM 1A is a simple to use, cost-effective and non-invasive advanced haemodynamic monitor that measures cardiovascular function, detects irregularities and is used to guide treatment. The USCOM 1A device has major applications in Paediatrics, Emergency, Intensive Care Medicine and Anaesthesia, and is the device of choice for management of adult and paediatric sepsis, hypertension, heart failure and for the guidance of fluid, inotrope and vasoactive cardiovascular therapy.

The Uscom BP+ is a supra systolic oscillometric Central Blood Pressure monitor which measures blood pressure and blood pressure waveforms only previously available using cardiac catheterisation. The Uscom BP+ replaces conventional and more widespread sub systolic blood pressure monitors, and is the emerging standard of care measurement in hypertension, heart failure and vascular health. The Uscom BP+ provides a highly accurate and repeatable measurement of central and brachial blood pressure and pulse pressure waveforms using a familiar upper arm cuff. The BP+ is simple to use and requires no complex training with applications in hypertension, heart failure, intensive care, general practice and home care.

Uscom SpiroSonic digital ultrasonic spirometers are high fidelity, digital, pulmonary function testing devices based on multi path ultrasound technology. They are simple and accurate to use and provide research quality pulmonary function testing in small hand held devices that can be used in research, clinical and home care environments. The devices are specialised for assessment of COPD, sleep disordered breathing, asthma, industrial diseases and monitoring of pulmonary therapeutic compliance.

For more information, please visit: www.uscom.com.au

Uscom Contacts

Associate Professor Rob Phillips Executive Chairman rob@uscom.com.au

Catherine Officer Company Secretary secretary@uscom.com.au

Uscom Limited (ABN 35 091 028 090) Suite 1, Level 7, 10 Loftus Street , Sydney NSW 2000 Australia , T +612 9247 4144 F +612 9247 8157 www.uscom.com.au